AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04633252
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
Trial: NCT06562985
Drug: BAY3018250 Dose 2 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, single dose
Trial: NCT06108076
Drug: Ketone Monoester (KE)
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
Trial: NCT05565820
Drug: Nix Creme Rinse Lice Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% permethrin lotion for topical application.
Trial: NCT05580991
Drug: CAN1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN1012 IT injection (once every 4 weeks)
Trial: NCT06545942
Drug: MOMA-313
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOMA-313 administered orally
Trial: NCT04746924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions will consist of a sterile, normal saline solution.
Trial: NCT05052255
Drug: RVU120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
Trial: NCT05602519
Drug: propofol, rocuronium and fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
Trial: NCT05296005
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05296005
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05296005
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06149520
Drug: BAY3018250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 or dose 2 of BAY3018250
Trial: NCT06149520
Drug: Placebo to BAY3018250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BAY3018250
Trial: NCT05627635
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05627635
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04199026
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via microdevice
Trial: NCT04199026
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via microdevice
Trial: NCT06265727
Drug: CRB-701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)
Trial: NCT00002005
Drug: CD4 Antigens
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06561711
Drug: Tetracycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT06561711
Drug: Minocycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT06556342
Drug: FRD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
Trial: NCT06454630
Drug: REGN7508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by single intravenous (IV) dose
Trial: NCT04661150
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
Trial: NCT06245083
Drug: Pyrroloquinoline quinone (PQQ)
RxNorm normalized name: pyrroloquinolinedione tricarboxylic acid
DrugBank: Pyrroloquinoline Quinone (DB03205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement taken daily
Trial: NCT05189756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo capsules for optical, acoustical and haptic blinding.
Trial: NCT05866861
Drug: CUG252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUG252 will be administered by subcutaneous injection.
Trial: NCT05866861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by subcutaneous injection.
Trial: NCT05763576
Drug: RO7565020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7565020 will be administered by subcutaneous injection or intravenous infusion.
Trial: NCT05763576
Drug: Nucleos(t)ide analogue (NUC) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
Trial: NCT04849988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
Trial: NCT05781009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04966585
Drug: Matching Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Trial: NCT04737330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
Trial: NCT06026163
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
Trial: NCT05532332
Drug: Fluoxetine 10 mg capsules
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
Trial: NCT05532332
Drug: Prozac® 10 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
Trial: NCT05005637
Drug: Anti Tuberculosis Drug
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
Trial: NCT05411978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo 90 mg for 12 weeks
Trial: NCT05287633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
Trial: NCT05810870
Drug: MEN1611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
Trial: NCT06177067
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Trial: NCT04745520
Drug: Analgesia
RxNorm normalized name: Analgesia Creme Rub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
Trial: NCT06099366
Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
Trial: NCT06099366
Drug: Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
Trial: NCT06099366
Drug: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
Trial: NCT06099366
Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
Trial: NCT06099366
Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
Trial: NCT06099366
Drug: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
Trial: NCT05402852
Drug: EuBone ® capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
Trial: NCT05402852
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
Trial: NCT06099366
Drug: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Trial: NCT06099366
Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Trial: NCT06326996
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given an infusion of thiamine.
Trial: NCT06326996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given an infusion of the placebo treatment.
Trial: NCT06334198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally once daily in the morning.
Trial: NCT05705492
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06585449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intrathecally
Trial: NCT05724797
Drug: NRS-033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of NRS-033 will be administered
Trial: NCT05724797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of matching placebo will be administered
Trial: NCT06431594
Drug: GSK5733584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK5733584 will be administered
Trial: NCT05633654
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally
Trial: NCT06374797
Drug: Auxora
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
Trial: NCT06374797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
Trial: NCT05664217
Drug: NKTR-255 at 1.5 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 at 1.5 µg/kg
Trial: NCT05664217
Drug: NKTR-255 at 3.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 at 3.0 μg/kg
Trial: NCT05664217
Drug: NKTR-255 at 3.0/6.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 at 3.0/6.0 μg/kg
Trial: NCT06274788
Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator
Trial: NCT05718778
Drug: Piamprimab (AK105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
Trial: NCT04947124
Drug: QLS-101ophthalmic solution 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-101ophthalmic solution 1.0%
Trial: NCT04947124
Drug: QLS-101ophthalmic solution 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-101ophthalmic solution 2.0%
Trial: NCT05928585
Drug: HIB210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental monoclonal antibody
Trial: NCT05928585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04754152
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
Trial: NCT01215890
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05835310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo via IV infusion
Trial: NCT00277836
Drug: MST-997
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05845736
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: number of hypertensive drugs
Trial: NCT04242329
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued PD1-inhibitor treatment according to current treatment standards.
Trial: NCT06255964
Drug: IAP0971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
Trial: NCT05303909
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Trial: NCT05303909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Trial: NCT05695352
Drug: Meloxicam 15 mg
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
Trial: NCT04338126
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: previously described
Trial: NCT06068465
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, capsule, once daily by mouth for 6 weeks
Trial: NCT04321551
Drug: Testosterone Cyp 200Mg/Ml Inj (in Oil)
RxNorm normalized name: TESTOSTERONE CYP 200MG/ML INJ (IN OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
Trial: NCT06196203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV injection
Trial: NCT06476392
Drug: Melatonin 10 MG
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
Trial: NCT06476392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
Trial: NCT04931342
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
Trial: NCT06220773
Drug: BR1019A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT06220773
Drug: BR1019B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT06220773
Drug: BR1019C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT06220773
Drug: BR1019A-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT06220773
Drug: BR1019B-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT06220773
Drug: BR1019C-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 12 weeks.
Trial: NCT05836805
Drug: [14C]XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
Trial: NCT05525013
Drug: Simvastatin Powder
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin gel placed as an intracanal medication
Trial: NCT05525013
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide intracanal medication
Trial: NCT06075264
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical placebo ointment
Trial: NCT05762211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT05836584
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05836584
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05836584
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV